Clinical trial

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

NCT00095888

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention triapine Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record gemcitabine hydrochloride Normalized identity: gemcitabine hydrochlorideView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention pharmacological study Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2004-10-01

PhasePHASE2

Conditions

Male Breast Cancerverified · MONDO: male breast carcinoma

Recurrent Breast Cancerunresolved

Stage IV Breast Cancerunresolved

Interventions

triapineDRUG

gemcitabine hydrochlorideDRUG · verified · RxNorm: gemcitabine hydrochloride

laboratory biomarker analysisOTHER

pharmacological studyOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

RochesterMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00095888 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.